Supriya Lifescience Ltd reported a 19% year-on-year revenue increase to Rs. 166 crores for Q2 FY25, with an EBITDA margin of 39% and a PAT margin of 28%, affirming its operational excellence and strategic focus on expanding its product portfolio.
AI Assistant
Supriya Lifescience Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.